1. Home
  2. CYCC

CYCC

Cyclacel Pharmaceuticals Inc.

Logo Cyclacel Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Founded: 1992 Country:
United States
United States
Employees: N/A City: BERKELEY HEIGHTS
Market Cap: 2.8M IPO Year: N/A
Target Price: $70.50 AVG Volume (30 days): 46.7K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -26.75 EPS Growth: N/A
52 Week Low/High: $1.82 - $13.20 Next Earning Date: 05-09-2024
Revenue: $420,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: